A recent study suggests that people who come off new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Research printed in a leading medical journal points out that while obese individuals frequently drop substantial amounts of their total mass while using the jabs, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users purchasing such drugs should be cognizant of the danger of fast rebound weight gain when the medication ends," warns researcher Dr. Susan Jebb.
This pace of regain implies a reversion to original mass in about a year and a half.
Weighing Approaches
The research, which examined 37 of studies involving over 9,000 of patients, contrasted the outcomes of these new drugs with older methods.
Scientists note that individuals who shed pounds through diet and exercise usually experience a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Experts suggest the mode of action of the jabs is key to understanding the accelerated rebound.
These medications mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in appetite is no longer kept in check, making binge eating far more likely."
A Chronic Issue?
Medical guidelines suggest the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.
A number of clinicians say that, given the significant potential of weight regain, the therapy should be considered long-term.
This view is reinforced by drug manufacturers, who state that the findings "emphasize the chronic character of obesity," comparing it to managing conditions like diabetes.
Patient Accounts
Individuals who have stopped the jabs explain a intense return of hunger.
"I experienced a switch flipping and I was suddenly ravenous," described a patient.
This challenge is exacerbated if patients have not adopted lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data show that a significant number of people in the UK have used these injections in the past year, with interest being substantial.
- Adoption is greater among females than males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, experts stress that while GLP-1 drugs are potent agents for weight loss, they are not a standalone solution and maintained weight loss likely depends on combined behavioural support.
